Trends in postpartum mental health care before and during COVID-19

Slawa Rokicki PhD1,2 | Maria W. Steenland SD3 | Caroline K. Geiger PhD4,5 | Rebecca A. Gourevitch PhD4,6 | Lucy Chen BS4 | Michelle W. Martin PhD7 | Jessica L. Cohen PhD2

1Department of Health Behavior, Society, & Policy, Rutgers School of Public Health, Piscataway, New Jersey, USA
2Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
3Population Studies and Training Center, Brown University, Providence, Rhode Island, USA
4Interfaculty Initiative in Health Policy, Harvard University, Cambridge, Massachusetts, USA
5Evidence for Access, Genentech, Inc., South San Francisco, California, USA
6Department of Health Policy and Management, University of Maryland, College Park, Maryland, USA
7Department of Social and Behavioral Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Correspondence
Slawa Rokicki, Department of Health Behavior, Society, & Policy, Rutgers School of Public Health, 683 Hoes Lane West, Piscataway, NJ, USA.
Email: slawa.rokicki@rutgers.edu

Abstract

Objective: To assess the impact of COVID-19 on trends in postpartum mental health diagnoses and utilization of psychotherapy and prescription drug treatment.

Data Sources: Data were obtained from a large, national health insurance claims database that tracks individuals longitudinally.

Study Design: We used interrupted time series models to examine changes in trends of postpartum mental health diagnoses before and during the COVID-19 pandemic and t-tests to examine differences in treatment.

Data Extraction Methods: We used billing codes to identify individuals who received mental health-related diagnoses and treatment in the first 90 days after a birth hospitalization. We excluded individuals diagnosed with schizophrenia or bipolar disorder and those with an unknown payer at delivery.

Principal Findings: Compared to the pre-pandemic period, the trend in new postpartum mental health diagnoses increased significantly in the post-COVID-19 period (0.06 percentage points [95%CI 0.01, 0.11]). Over 12 months, the percentage of new diagnoses was 5.0% greater relative to what would be expected in absence of COVID-19. The percentage of diagnosed individuals who did not receive treatment increased from 50.4% to 52.7% (p = 0.003).

Conclusions: Findings point to an urgent need to improve screening and treatment pathways for perinatal individuals in the wake of COVID-19.

KEYWORDS
COVID-19, COVID-19 research database, interrupted time series, Medicaid, mental health, perinatal depression

What is known on this topic
- The COVID-19 pandemic increased stress, depression, and anxiety among perinatal individuals.
- Previous studies have found high rates of foregone mental health care following the onset of the pandemic in the general population.
1 | INTRODUCTION

Postpartum depression and anxiety affect 11%-22% of pregnant and postpartum individuals, with higher rates among those who are non-White, younger, and with lower education. Untreated postpartum mental health conditions can lead to adverse health and social outcomes for both mother and child. Systematic reviews have found that the COVID-19 pandemic and associated economic downturn increased stress, depression, and anxiety among perinatal individuals through a variety of channels, including fear of the virus, social isolation, inadequate childcare, and financial instability. Studies have found high rates of foregone mental health care following the onset of the pandemic in the general population, with slow and incomplete rebound rates, particularly among Medicaid beneficiaries. However, little is known about the utilization of mental health care during the COVID-19 pandemic among pregnant and postpartum individuals.

In this study, we assessed the impact of COVID-19 on postpartum mental health care utilization, including the rates of diagnoses and utilization of psychotherapy and prescription drug treatment using a large, national health insurance claims database.

2 | METHODS

2.1 | Data and study sample

We conducted a retrospective observational analysis using health insurance claims data from Symphony Health, a claims clearinghouse that covers an estimated 16,000 health plans, 1500 hospitals, 280 million patients, 1.9 million practitioners, and 93% of prescriptions dispensed in the U.S. Data were provided by the COVID-19 Research Database. The data include patients tracked longitudinally even if they switched insurers or pharmacies, as long as the practitioner or pharmacy is covered by the clearinghouse. Data included diagnosis, procedure, and prescription drug codes. The data extract included all claims between May 01, 2019 and June 30, 2021.

We identified individuals who gave birth using childbirth ICD-10 codes (Appendix A1). Consistent with prior research, individuals were required to meet one of the following requirements on the date of delivery: (1) two unique delivery-related diagnosis codes, (2) two unique delivery-related procedure codes, or (3) one delivery-related diagnosis and one delivery-related procedure code. Dates with two or more delivery-related diagnosis and/or procedure codes within 100 days of each other were grouped together and the date with the greatest number of diagnosis and/or procedure codes was flagged as the date of delivery. When an individual had more than one birth episode during the study period (3% of births), we randomly chose one birth to maintain the independence of observations. We excluded individuals diagnosed with schizophrenia or bipolar disorder because of different treatment requirements for these mental illnesses (2%). Finally, we excluded individuals whose birth was financed by an unknown payer (7%). To observe a 90-day postpartum period for all individuals, we restricted our analytic sample to individuals who gave birth before March 31, 2021.

2.2 | Outcomes

Following previous literature, we used billing codes to identify individuals’ mental health-related diagnoses (depression, anxiety, or stress-reaction), outpatient treatment (psychotherapy), and pharmaceuticals (antidepressants, anxiolytics). Appendix A2 includes details on the codes used. For pharmaceuticals, we restricted the data to pharmacies that reported claims every month to the database throughout the data extract period (96% of all pharmacy claims), in order to maintain a consistent sample of pharmacies in the database. We calculated the percentage of individuals giving birth in a particular month who received a mental health diagnosis in the first 90 days postpartum, beginning on the day of the birth hospitalization. In order to separate new cases of depression or anxiety from ongoing illness, we separately examined all diagnoses and “new diagnoses,” which we defined as diagnoses among individuals who did not have a claim for a mental health diagnosis or treatment in the last 90 days of their pregnancy (prior to the delivery hospitalization).

2.3 | Analyses

We defined the pre-COVID period as deliveries from May to December 2019 for all diagnoses and deliveries from August to...
December 2019 for new diagnoses to allow for 90 days of prenatal data for all individuals. The post-COVID period was defined as deliveries that occurred after the start of the COVID pandemic, that is, April 2020 to March 2021. Deliveries from January to March 2020 were excluded from analyses because the 90-day postpartum period for individuals giving birth in those periods was partially affected by COVID-19.

First, we used segmented linear regression interrupted time series models with Newey-West standard errors to examine changes in the trend of postpartum mental health diagnoses between pre-COVID and post-COVID periods. The model included level and trend parameters at two change points (January 2020 and April 2020). Model specification details are provided in Appendix A3. We estimated separate models for all diagnoses and for new diagnoses. As level changes were not apparent, we present only changes in trends in the main results. Full results are shown in Appendix A3. Finally, we conducted t-tests to examine differences in treatment use among those with a diagnosis (no treatment, prescription drug treatment, and psychotherapy treatment) in the pre-COVID compared to the post-COVID period.

Analyses were conducted overall for the full sample and stratified by type of payer at delivery. In sensitivity analyses, we examined results without excluding the partially treated months from the analysis, beginning the post-COVID period from January 2020. Data were analyzed using Stata version 16.

3 | RESULTS

There were 2,088,981 individuals who gave birth during the study period, with 637,907 (30.5%) who were insured by Medicaid and 1,451,074 (69.5%) who were insured by commercial insurance. The average age at birth was 27 years for Medicaid-insured births compared to 30 years for the commercially insured (Appendix A4). The rate of preterm births was 12.3% among Medicaid-insured compared to 8.9% among commercially insured individuals, while the cesarean section rate was similar (40.7 vs. 39.8%). While the average age at birth and preterm birth rates were very similar to the average in U.S. natality data, the rates of cesarean section in our data were higher (Appendix A4).

Figure 1 shows trends in new postpartum mental health diagnoses during the pre- and post-COVID periods. In December 2019, 6.1% of individuals received a new mental health diagnosis code in the first 90 days postpartum. There was a marked reduction in diagnoses for individuals who gave birth during the initial months of COVID-19 (February and March 2020), likely the result of interrupted service delivery in the initial course of the pandemic. The pre-COVID period, there was a slowly increasing trend in new postpartum mental health diagnoses. The trend in new postpartum mental health diagnoses post-COVID significantly increased relative to the pre-COVID period (difference in slope pre- and post-COVID, 0.06 percentage points [95% CI, 0.01, 0.11]) (Table 1). Appendix A3 shows the full regression output showing both level and trend estimates. Over the 12-month period from April 2020 to March 2021, the percentage of new diagnoses was 5.0% greater relative to what would be expected in the absence of COVID-19. Appendix A5 shows these trends stratified by the payer at delivery. There was a statistically significant 0.08 pp (95% CI, 0.02, 0.13) increase in the trend for new diagnoses for the commercially insured; the change among the Medicaid insured was not statistically significant (0.02 pp [95% CI, −0.05, 0.08]).

The difference in slope between pre-COVID and post-COVID periods was slightly smaller for all diagnoses, with similar patterns for commercially versus Medicaid insured. Changes in trends in postpartum diagnoses were not sensitive to including January–March 2020 as part of the post-COVID-19 period (Appendix A6). Similar patterns were observed for depression and anxiety diagnoses, while there was no change in stress-reaction diagnoses (Appendix A7).

Figure 2 shows the percentage of individuals with diagnoses who also received a claim for prescription drug treatment, psychotherapy treatment, or no treatment in the pre- and post-COVID-19 periods. In the Medicaid group, 54.0% received neither a prescription drug nor psychotherapy treatment in the pre-COVID period. This treatment gap increased to 57.1% in the post-COVID period ($p = 0.001$) (Appendix A8). For commercially insured, the percentage with no treatment increased from 48.5% to 50.4% ($p = 0.007$). The decrease in treatment was driven by a decrease in the percentage of individuals who received prescription drug treatment (39.7% to 35.7%)}
There was a small but significant increase in the percentage of individuals with psychotherapy treatment among the commercially insured (11.1% to 12.3%, \( p < 0.001 \)), an increase of 11 percent over the pre-pandemic level. The increase was smaller for the Medicaid insured (10.1% to 10.6%, \( p = 0.09 \)).

We found that the COVID-19 pandemic was associated with increases in diagnoses of postpartum mental health conditions, a finding consistent with systematic reviews indicating worsening perinatal mental health as a result of the pandemic. Commercially-insured postpartum individuals experienced larger increases than those who were Medicaid-insured. This finding may be counterintuitive considering that other studies found that low-income pregnant women (e.g., those who qualify for Medicaid) experienced more pandemic-related stressors, including financial, social, health and health care, and childcare. The finding may reflect that commercially-insured individuals were more likely be diagnosed than their Medicaid-insured peers, regardless of underlying depression prevalence. Compared to commercial insurance, Medicaid offers more limited coverage of mental health services and beneficiaries may have experienced difficulty finding clinicians who accept Medicaid payment rates. Expanded access to telehealth during the pandemic for Medicaid beneficiaries may have been hampered by lower digital literacy and unreliable Internet services.

Half of all diagnosed postpartum individuals received no prescription drug or psychotherapy treatment in the first 90 days postpartum, which is consistent with recent evidence on the pandemic’s disruption of mental health care. These decreases may be the result of low demand (e.g., if treatment was unaffordable, particularly for those already financially strapped), insufficient supply (e.g., if services were unavailable, particularly in the early stage of the pandemic), or a combination of both. Use of psychotherapy increased slightly for people with commercial insurance. The change may have been the result of increased access to telehealth services;
Unfortunately, we were not able to discern telehealth from in-person diagnoses in our data. The analysis had several limitations. We examine mental health during the first 90 days postpartum. While the vast majority of postpartum depression diagnoses occur in this period, we miss diagnoses that occur later. The data is available only from May 2019, providing a short pre-pandemic period and limiting our ability to adjust our models for seasonality. We also could not examine trends by race, education, or other factors predictive of perinatal mental health. Administrative claims data have limitations, including lack of population representativeness, undercoding of mental health conditions, and inability to observe screening patterns or forms of treatment such as peer support groups that may have seen changes in use over the pandemic. Finally, many perinatal mental health conditions are neither diagnosed nor treated; as this study relies on claims data, it cannot provide an assessment of the change in the prevalence of mental health conditions during the pandemic.

4.1 | Implications for policy and practice

We found that the trend in postpartum mental health diagnoses increased significantly in the post-COVID period compared to 2019. We also found increases in the percentage of diagnosed individuals who did not access treatment. These findings emphasize the importance of improving screening and treatment pathways for perinatal individuals in the wake of the COVID-19 pandemic. Possible policy solutions may include extending Medicaid to 12 months of postpartum coverage, ensuring coordination of services for mothers and infants through co-located facilities, expanding insurance coverage of community-based maternal care, and increasing access to psychiatric telehealth services.

ACKNOWLEDGMENTS

The data, technology, and services used in the generation of these research findings were generously supplied pro bono by the COVID-19 Research Database partners, who are acknowledged at https://covid19researchdatabase.org/.

FUNDING INFORMATION

Lucy Chen’s involvement in the project was supported by award numbers T32GM007753 and T32GM144273 from the National Institute of General Medicine Sciences and T32AG51108 from the National Institute on Aging. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Caroline Geiger’s involvement in the project was supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE1745303. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. The study was conceived while Caroline Geiger was a PhD candidate at Harvard University, and the findings and views in this article do not reflect the official views or policy of Genentech Inc. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of Genentech.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ORCID

Slawa Rokicki https://orcid.org/0000-0001-9176-373X
Caroline K. Geiger https://orcid.org/0000-0001-8616-8450
Rebecca A. Gourevitch https://orcid.org/0000-0001-7656-0811
Lucy Chen https://orcid.org/0000-0001-6369-0916

REFERENCES

1. Lara-Cinsomo S, Clark CT, Wood J. Increasing diagnosis and treatment of perinatal depression in Latinas and African American women: addressing stigma is not enough. Womens Health Issues. 2018;28(3):201-204.
2. Bauman BL. Vital signs: postpartum depressive symptoms and provider discussions about perinatal depression — United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69:575-581.
3. Egmose I, Tharnier A, Liebenberg KB, Steenhoff T, Vaver MS. Long-term effects of maternal postpartum depression on mothers’ and fathers’ parenting stress. Early Child Dev Care. 2020;29:1-13. doi:10.1080/03004430.2020.1755663
4. Moore JE, McLemore MR, Glenn N, Zivin K. Policy opportunities to improve prevention, diagnosis, and treatment of perinatal mental health conditions. Health Aff. 2021;40(10):1534-1542. doi:10.1377/hlthaff.2021.00779
5. Rokicki S, McGovern M, Von Jaglinsky A, Reichman NE. Depression in the postpartum year and life course economic trajectories. Am J Prev Med. 2021;50749–3797(21):486-484. doi:10.1016/j.amepre.2021.08.011
6. McGovern ME, Rokicki S, Reichman NE. Maternal depression and economic well-being: A quasi-experimental approach. Social Science & Medicine. 2022;305:115017. https://doi.org/10.1016/j.socscimed.2022.115017
7. Shuffrey LC, Thomason ME, Brito NH. Improving perinatal maternal mental health starts with addressing structural inequities. JAMA Psychiatry. 2022;79(5):387-388. doi:10.1001/jamapsychiatry.2022.0097
8. Tomfohr-Madsen LM, Racine N, Giesbrecht GF, Lebel C, Madigan S. Depression and anxiety in pregnancy during COVID-19: a rapid review and meta-analysis. Psychiatry Res. 2021;300:113912. doi:10.1016/j.psychres.2021.113912
9. Nason I, Stein DT, Frank RG, Stein MB. Decline in new starts of psychotropic medications during the COVID-19 pandemic. Health Aff. 2021;40(6):904-909. doi:10.1377/hlthaff.2021.00028
10. Steenland MW, Geiger CK, Chen L, et al. Declines in contraceptive visits in the United States during the COVID-19 pandemic. Contraception. 2021;104(6):593-599. doi:10.1016/j.contraception.2021.08.003
11. Geiger CK, Clapp MA, Cohen JL. Association of Prenatal Care Services, maternal morbidity, and perinatal mortality with the advanced maternal age cutoff of 35 years. JAMA Health Forum. 2021;2(12):e214044. doi:10.1001/jamahealthforum.2021.4044
12. Kozhimannil KB, Adams AS, Soumerai SB, Busch AB, Huskamp HA. New Jersey’s efforts to improve postpartum depression care did not change treatment patterns for women on Medicaid. Health Aff (Millwood). 2011;30(2):293-301. doi:10.1377/hlthaff.2009.1075
13. Sherman LJ, Ali MM. Diagnosis of postpartum depression and timing and types of treatment received differ for women with private and Medicaid coverage. Womens Health Issues. 2018;28(6):524-529. doi:10.1016/j.whi.2018.08.007
14. Avalos LA, Nance N, Zhu Y, et al. Contributions of COVID-19 pandemic-related stressors to racial and ethnic disparities in mental health during pregnancy. *Front Psych.* 2022;13:837659. doi:10.3389/fpsyg.2022.837659

15. Byatt N, Biebel K, Lundquist RS, et al. Patient, provider, and system-level barriers and facilitators to addressing perinatal depression. *J Reprod Infant Psychol.* 2012;30(5):436-449. doi:10.1080/02646838.2012.743000

16. Bhat A, Miller ES, Wendt A, Ratzliff A. Finding a medical home for perinatal depression: how can we bridge the postpartum gap? *Womens Health Issues.* 2020;30(6):405-408. doi:10.1016/j.whi.2020.08.010

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Rokicki S, Steenland MW, Geiger CK, et al. Trends in postpartum mental health care before and during COVID-19. *Health Serv Res.* 2022;57(6):1342-1347. doi:10.1111/1475-6773.14051